{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:23:12Z","timestamp":1740144192445,"version":"3.37.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,3,26]],"date-time":"2018-03-26T00:00:00Z","timestamp":1522022400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["Project number 15\/121\/14"],"award-info":[{"award-number":["Project number 15\/121\/14"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s40273-017-0608-z","type":"journal-article","created":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T23:35:59Z","timestamp":1522798559000},"page":"545-553","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Reslizumab for Treating Asthma with Elevated Blood Eosinophils Inadequately Controlled by Inhaled Corticosteroids: An Evidence Review Group Perspective of a NICE Single Technology Appraisal"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0318-7670","authenticated-orcid":false,"given":"Keith","family":"Cooper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoff","family":"Frampton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micah","family":"Rose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Chorozoglou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Pickett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,26]]},"reference":[{"key":"608_CR1","unstructured":"National Institute for Health and Care Excellence. Asthma (eosinophilic)\u2014reslizumab (after inhaled corticosteroids). 2017. https:\/\/www.nice.org.uk\/guidance\/ta479 . Accessed Oct 2017."},{"key":"608_CR2","unstructured":"National Institute for Health and Care Excellence. 2017. https:\/\/www.nice.org.uk\/ . Accessed Oct 2017."},{"key":"608_CR3","unstructured":"Asthma UK. Asthma facts and statistics. 2016. https:\/\/www.asthma.org.uk\/about\/media\/facts-and-statistics\/ . Accessed Oct 2017."},{"key":"608_CR4","unstructured":"Asthma UK. 2017. https:\/\/www.asthma.org.uk\/about\/media\/news\/asthma-uk-study-1.1bn\/ . Accessed Oct 2017"},{"key":"608_CR5","doi-asserted-by":"crossref","unstructured":"European Respiratory Society (ERS). Assessing asthma quality of life: its role in clinical practice. 2005. http:\/\/breathe.ersjournals.com\/content\/breathe\/1\/3\/192.full.pdf . Accessed Oct 2017.","DOI":"10.1183\/18106838.0103.192"},{"key":"608_CR6","unstructured":"British Thoracic Society and Scottish Intercollegiate Guidelines Network. SIGN 141. British Guideline on the Management of Asthma. 2014."},{"key":"608_CR7","unstructured":"Global Initiative for Asthma. Global strategy for asthma management and prevention (2016 update). 2016. http:\/\/ginasthma.org\/wp-content\/uploads\/2016\/04\/GINA-2016-main-report_tracked.pdf . Accessed Oct 2017."},{"issue":"Suppl. 57","key":"608_CR8","first-page":"P4177","volume":"42","author":"F Novelli","year":"2013","unstructured":"Novelli F, Lenzini G, Latorre M, Seccia V, Bartoli ML, Malagrin\u00f2 L, et al. Influence of obesity and nasal polyps on severe asthma. Eur Respir J. 2013;42(Suppl. 57):P4177.","journal-title":"Eur Respir J."},{"issue":"4","key":"608_CR9","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jaci.2012.07.017","volume":"130","author":"PJ Chang","year":"2012","unstructured":"Chang PJ, Bhavsar PK, Michaeloudes C, Khorasani N, Chung KF. Corticosteroid insensitivity of chemokine expression in airway smooth muscle of patients with severe asthma. J Allergy Clin Immunol. 2012;130(4):877\u201385.","journal-title":"J Allergy Clin Immunol."},{"issue":"3","key":"608_CR10","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","volume":"60","author":"M Humbert","year":"2005","unstructured":"Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60(3):309\u201316.","journal-title":"Allergy"},{"key":"608_CR11","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","volume":"3","author":"M Castro","year":"2015","unstructured":"Castro M, Zangrilli J, Wechsler M, Bateman E, Brusselle G, Bardin P, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3:355\u201366.","journal-title":"Lancet Respir Med."},{"issue":"4","key":"608_CR12","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.chest.2016.03.032","volume":"150","author":"L Bjermer","year":"2016","unstructured":"Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016;150(4):789\u201398.","journal-title":"Chest."},{"issue":"4","key":"608_CR13","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","volume":"150","author":"J Corren","year":"2016","unstructured":"Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016;150(4):799\u2013810.","journal-title":"Chest."},{"key":"608_CR14","first-page":"1126","volume":"184","author":"M Castro","year":"2011","unstructured":"Castro M, Mathur S, Hargreave F, Boulet L-P, Xie F, Young J, et al. Reslizumab for poorly controlled, eosinophilic asthma. A randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184:1126\u201332.","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"608_CR15","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","volume":"187","author":"N Hanania","year":"2013","unstructured":"Hanania N, Wenzel S, Rosen K, Hsieh H-J, Mosesova S, Choy D, et al. Exploring the effects of omalizumab in allergic asthma. Am J Respir Crit Care Med. 2013;187(8):804\u201311.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"608_CR16","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40258-014-0107-8","volume":"12","author":"J Willson","year":"2014","unstructured":"Willson J, Bateman ED, Pavord I, Lloyd A, Krivasi T, Esser D. Cost effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and long-acting beta-agonists. Appl Health Econ Health Policy. 2014;12(4):447\u201359.","journal-title":"Appl Health Econ Health Policy."},{"issue":"1","key":"608_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3132\/pcrj.2007.00002","volume":"16","author":"A Lloyd","year":"2007","unstructured":"Lloyd A, Price D, Brown R. The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim Care Respir J. 2007;16(1):22\u20137.","journal-title":"Prim Care Respir J."},{"key":"608_CR18","unstructured":"National Institute for Health and Care Excellence. Single Technology Appraisal. Mepolizumab for treating severe eosinophilic asthma [ID798]. Committee papers 2016. https:\/\/www.nice.org.uk\/guidance\/ta431 . Accessed Oct 2017."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-017-0608-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-017-0608-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-017-0608-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,13]],"date-time":"2019-10-13T21:54:30Z","timestamp":1571003670000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-017-0608-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,26]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["608"],"URL":"https:\/\/doi.org\/10.1007\/s40273-017-0608-z","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"type":"print","value":"1170-7690"},{"type":"electronic","value":"1179-2027"}],"subject":[],"published":{"date-parts":[[2018,3,26]]},"assertion":[{"value":"26 March 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This work was funded by the National Institute for Health Research Health Technology Assessment programme as Project number 15\/121\/14.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors (KC, GF, PH, MR, MC and KP) had no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}